Pegavision Corporation (TPE:6491)
Taiwan · Delayed Price · Currency is TWD 305.00
-3.00 (-0.97%)
Dec 3, 2025, 1:30 PM CST
Pegavision Revenue
Pegavision had revenue of 1.89B TWD in the quarter ending September 30, 2025, with 13.84% growth. This brings the company's revenue in the last twelve months to 6.90B, down -2.22% year-over-year. In the year 2024, Pegavision had annual revenue of 6.82B with 0.40% growth.
Revenue (ttm)
6.90B
Revenue Growth
-2.22%
P/S Ratio
3.45
Revenue / Employee
n/a
Employees
n/a
Market Cap
23.79B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6.82B | 27.44M | 0.40% |
| Dec 31, 2023 | 6.79B | 468.66M | 7.41% |
| Dec 31, 2022 | 6.32B | 726.16M | 12.98% |
| Dec 31, 2021 | 5.60B | 1.62B | 40.64% |
| Dec 31, 2020 | 3.98B | 623.28M | 18.58% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bora Pharmaceuticals Co., LTD. | 21.10B |
| Lotus Pharmaceutical | 18.66B |
| PharmaEssentia | 13.82B |
| Sunmax Biotechnology | 2.00B |
| Center Laboratories | 1.57B |
| Oneness Biotech | 117.33M |
| Polaris Group | 70.83M |
| Lumosa Therapeutics | 42.59M |